Publication - Progress report
New Medicines Reviews 2013
Reports on the role of SMC & Review of IPTR & ADTC
Appendix 3: Breakdown of NHS boards' ADTC decisions
The table below Indicates each board's breakdown of medicines into the six decision categories
| ADTC decision categories* | ||||||
|---|---|---|---|---|---|---|
| Board | 1 | 2 | 3 | 4 | 5 | 6 |
| NHS A&A | 15 (65%) | 2 (9%) | 0 (0%) | 2 (9%) | 1 (4%) | 3 (13%) |
| NHS Borders | 17 (74%) | 0 (0%) | 1 (4%) | 1 (4%) | 0 (0%) | 4 (17%) |
| NHS D&G | 8 (35%) | 5 (22%) | 3 (13%) | 0 (0%) | 3 (13%) | 4 (17%) |
| NHS Fife | 21 (91%) | 0 (0%) | 0 (0%) | 1 (4%) | 1 (4%) | 0 (0%) |
| NHS FV | 20 (87%) | 0 (0%) | 0 (0%) | 3 (13%) | 0 (0%) | 0 (0%) |
| NHS Grampian | 14 (61%) | 1 (4%) | 0 (0%) | 2 (9%) | 6 (26%) | 0 (0%) |
| NHS GG&C | 20 (87%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 3 (13%) |
| NHS Highland | 15 (65%) | 0 (0%) | 0 (0%) | 8 (35%) | 0 (0%) | 0 (0%) |
| NHS Lanarkshire | 23 (100%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| NHS Lothian | 11 (48%) | 2 (9%) | 0 (0%) | 3 (13%) | 3 (13%) | 4 (17%) |
| NHS Orkney | No Data Provided - as per NHS Grampian | |||||
| NHS Shetland | No Data Provided - as per NHS Grampian | |||||
| NHS Tayside | 18 (78%) | 0 (0%) | 0 (0%) | 3 (13%) | 0 (0%) | 2 (9%) |
| NHS WI | 15 (65%) | 0 (0%) | 0 (0%) | 8 (35%) | 0 (0%) | 0 (0%) |
| Average | 16 medicines | 1 medicines | 0 medicine | 3 medicines | 1 medicine | 2 medicines |
| Average % | 70% | 4% | 0% | 13% | 4% | 9% |
* ADTC decision categories:
- Included on the NHS board formulary (to include specialist, approved, additional lists) for the indication in question.
- Included pending protocol.
- Not included* from the NHS board formulary because the NHS board decision is that the medicine does not represent sufficient added benefit to other comparator medicines to treat the condition in question which are already available in the formulary.
- Not included* from the NHS board formulary because clinicians do not support the formulary inclusion.
- Not included* from the NHS board formulary because clinicians have not responded to an invitation to apply for formulary inclusion for this medicine;
- Not included* pending protocol.
Contact
Email: VERONICA MOFFAT
There is a problem
Thanks for your feedback